Author: Durand, Nisha; Mallea, Jorge; Zubair, Abba C.
Title: Insights into the use of mesenchymal stem cells in COVID-19 mediated acute respiratory failure Cord-id: l3pctamd Document date: 2020_10_26
ID: l3pctamd
Snippet: The emergence of severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) at the end of 2019 in Hubei province China, is now the cause of a global pandemic present in over 150 countries. COVID-19 is a respiratory illness with most subjects presenting with fever, cough and shortness of breath. In a subset of patients, COVID-19 progresses to hypoxic respiratory failure and acute respiratory distress syndrome (ARDS), both of which are mediated by widespread inflammation and a dysregulated immu
Document: The emergence of severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) at the end of 2019 in Hubei province China, is now the cause of a global pandemic present in over 150 countries. COVID-19 is a respiratory illness with most subjects presenting with fever, cough and shortness of breath. In a subset of patients, COVID-19 progresses to hypoxic respiratory failure and acute respiratory distress syndrome (ARDS), both of which are mediated by widespread inflammation and a dysregulated immune response. Mesenchymal stem cells (MSCs), multipotent stromal cells that mediate immunomodulation and regeneration, could be of potential benefit to a subset of COVID-19 subjects with acute respiratory failure. In this review, we discuss key features of the current COVID-19 outbreak, and the rationale for MSC-based therapy in this setting, as well as the limitations associated with this therapeutic approach.
Search related documents:
Co phrase search for related documents- activate immune response and acute ards respiratory distress syndrome: 1
- activate immune response and acute respiratory syndrome: 1, 2, 3, 4, 5, 6
Co phrase search for related documents, hyperlinks ordered by date